Back to Directory

Michelle Haber

Email

mhaber@fhi360.org

Phone

919-321-3472

Institution

FHI 360

Title

Community Programs Associate

Address

FHI360
359 Blackwell St.
Ste 200
Durham, NC 27701

Request an Update

Affiliated Studies

IMPAACT 2016: Evaluating a Group-Based Intervention to Improve Mental Health and ART Adherence Among Youth Living with HIV in Low Resource Settings

DAIDS Number

38506

Research Area

Brain and Mental Health

Study Status

Closed to Accrual

IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum.

DAIDS Number

38609

Research Area

Therapeutics

Study Status

Closed to Accrual

IMPAACT 2021: Randomized Phase I/II Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV delta NS2/ delta 1313/I1314L, RSV 6120/ delta NS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age

DAIDS Number

38530

Research Area

Cure and Immunotherapy

Study Status

Participants Off Study and Primary Analysis Completed

IMPAACT 2037: Open-Label, Phase I Study of the Safety and Pharmacokinetics of PGT121.414.LS alone and in combination with VRC07-523LS in Infants Exposed to HIV-1

DAIDS Number

38962

Research Area

Therapeutics

Study Status

Pending

IMPAACT 2034: Phase 1 Study of the Pharmacokinetics, Safety, and Acceptability of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children with Rifampicin-Resistant Tuberculosis

DAIDS Number

38754

Research Area

Tuberculosis

Study Status

Enrolling

Show All